Uncategorized
Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/DME?src=hash" target="_blank">#DME</a>--Allegro Ophthalmics announced that results of its risuteganib US Phase 2 dry AMD study will be presented at EURETINA and The Retina Society meeting.